Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients

Satohiro Masuda, Shinji Uemoto, Maki Goto, Yasuhiro Fujimoto, Koichi Tanaka, Ken Ichi Inui

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

To clarify the clinical applicability of intestinal absorptive barriers, we have quantified messenger ribonucleic acid (mRNA) expression levels of multidrug resistance 1 (MDR1) protein and cytochrome P450 (CYP) 3A4 in intestinal biopsy specimens from 2 small-bowel transplant recipients. Postoperative immunosuppressive therapy was started with intravenous and oral administrations of tacrolimus and a small amount of steroids. The daily dosage of tacrolimus was modified mainly on the basis of trough levels. After confirmation that the enterocyte MDR1 level was decreasing, tacrolimus was administered via the oral route only. The mRNA levels in the biopsy specimens varied widely throughout the period. With high-dose steroid-pulse treatment, the enterocyte mRNA expression of CYP3A4, but not of MDR1, was markedly enhanced. The mRNA levels of MDR1, but not CYP3A4, correlated well with the concentration/oral dose ratio and the oral dosage of tacrolimus. The good progress after transplantation in both cases suggested that monitoring the change in expression of MDR1 mRNA in the graft intestine might be helpful for understanding the pharmacokinetic profile and determining when to change the route of tacrolimus administration in small-bowel transplant recipients.

Original languageEnglish
Pages (from-to)352-361
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume75
Issue number4
DOIs
Publication statusPublished - Apr 1 2004
Externally publishedYes

Fingerprint

Multiple Drug Resistance
Tacrolimus
Cytochrome P-450 CYP3A
RNA
Enterocytes
Steroids
Biopsy
Therapeutics
P-Glycoprotein
Immunosuppressive Agents
Intravenous Administration
Intestines
Oral Administration
Pharmacokinetics
Transplantation
Transplant Recipients
Transplants

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. / Masuda, Satohiro; Uemoto, Shinji; Goto, Maki; Fujimoto, Yasuhiro; Tanaka, Koichi; Inui, Ken Ichi.

In: Clinical Pharmacology and Therapeutics, Vol. 75, No. 4, 01.04.2004, p. 352-361.

Research output: Contribution to journalArticle

Masuda, Satohiro ; Uemoto, Shinji ; Goto, Maki ; Fujimoto, Yasuhiro ; Tanaka, Koichi ; Inui, Ken Ichi. / Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. In: Clinical Pharmacology and Therapeutics. 2004 ; Vol. 75, No. 4. pp. 352-361.
@article{58ef79ed81af46bd804bca885a33bd2a,
title = "Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients",
abstract = "To clarify the clinical applicability of intestinal absorptive barriers, we have quantified messenger ribonucleic acid (mRNA) expression levels of multidrug resistance 1 (MDR1) protein and cytochrome P450 (CYP) 3A4 in intestinal biopsy specimens from 2 small-bowel transplant recipients. Postoperative immunosuppressive therapy was started with intravenous and oral administrations of tacrolimus and a small amount of steroids. The daily dosage of tacrolimus was modified mainly on the basis of trough levels. After confirmation that the enterocyte MDR1 level was decreasing, tacrolimus was administered via the oral route only. The mRNA levels in the biopsy specimens varied widely throughout the period. With high-dose steroid-pulse treatment, the enterocyte mRNA expression of CYP3A4, but not of MDR1, was markedly enhanced. The mRNA levels of MDR1, but not CYP3A4, correlated well with the concentration/oral dose ratio and the oral dosage of tacrolimus. The good progress after transplantation in both cases suggested that monitoring the change in expression of MDR1 mRNA in the graft intestine might be helpful for understanding the pharmacokinetic profile and determining when to change the route of tacrolimus administration in small-bowel transplant recipients.",
author = "Satohiro Masuda and Shinji Uemoto and Maki Goto and Yasuhiro Fujimoto and Koichi Tanaka and Inui, {Ken Ichi}",
year = "2004",
month = "4",
day = "1",
doi = "10.1016/j.clpt.2003.11.374",
language = "English",
volume = "75",
pages = "352--361",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients

AU - Masuda, Satohiro

AU - Uemoto, Shinji

AU - Goto, Maki

AU - Fujimoto, Yasuhiro

AU - Tanaka, Koichi

AU - Inui, Ken Ichi

PY - 2004/4/1

Y1 - 2004/4/1

N2 - To clarify the clinical applicability of intestinal absorptive barriers, we have quantified messenger ribonucleic acid (mRNA) expression levels of multidrug resistance 1 (MDR1) protein and cytochrome P450 (CYP) 3A4 in intestinal biopsy specimens from 2 small-bowel transplant recipients. Postoperative immunosuppressive therapy was started with intravenous and oral administrations of tacrolimus and a small amount of steroids. The daily dosage of tacrolimus was modified mainly on the basis of trough levels. After confirmation that the enterocyte MDR1 level was decreasing, tacrolimus was administered via the oral route only. The mRNA levels in the biopsy specimens varied widely throughout the period. With high-dose steroid-pulse treatment, the enterocyte mRNA expression of CYP3A4, but not of MDR1, was markedly enhanced. The mRNA levels of MDR1, but not CYP3A4, correlated well with the concentration/oral dose ratio and the oral dosage of tacrolimus. The good progress after transplantation in both cases suggested that monitoring the change in expression of MDR1 mRNA in the graft intestine might be helpful for understanding the pharmacokinetic profile and determining when to change the route of tacrolimus administration in small-bowel transplant recipients.

AB - To clarify the clinical applicability of intestinal absorptive barriers, we have quantified messenger ribonucleic acid (mRNA) expression levels of multidrug resistance 1 (MDR1) protein and cytochrome P450 (CYP) 3A4 in intestinal biopsy specimens from 2 small-bowel transplant recipients. Postoperative immunosuppressive therapy was started with intravenous and oral administrations of tacrolimus and a small amount of steroids. The daily dosage of tacrolimus was modified mainly on the basis of trough levels. After confirmation that the enterocyte MDR1 level was decreasing, tacrolimus was administered via the oral route only. The mRNA levels in the biopsy specimens varied widely throughout the period. With high-dose steroid-pulse treatment, the enterocyte mRNA expression of CYP3A4, but not of MDR1, was markedly enhanced. The mRNA levels of MDR1, but not CYP3A4, correlated well with the concentration/oral dose ratio and the oral dosage of tacrolimus. The good progress after transplantation in both cases suggested that monitoring the change in expression of MDR1 mRNA in the graft intestine might be helpful for understanding the pharmacokinetic profile and determining when to change the route of tacrolimus administration in small-bowel transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=1842737790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842737790&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2003.11.374

DO - 10.1016/j.clpt.2003.11.374

M3 - Article

C2 - 15060513

AN - SCOPUS:1842737790

VL - 75

SP - 352

EP - 361

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -